ALFA Finder| Management target | Revenue 32.5% FY28 |
|---|
| Revenue growth | 31.2% YoY growth in Q1 FY27. |
|---|---|
| Margins | EBITDA impacted by leadership hires and remediation costs; mid-teens target post-EU. |
| Order book | Received first product order from Australia. |
| Demand visibility | Strong export resilience; expectations for EU market supplies by Q4. |
| Management confidence | High, pending EU-GMP certification finalization. |
Growth
Revenue reached INR 942 million (+31.2% YoY). EBITDA stood at INR 34 million with 3.7% margin; PAT was a loss of INR 40 million.
Outlook
Management guides 30-35% revenue growth for FY28 post-EU-GMP; FY27 growth expected at 10-15% without EU. Capex of INR 15-20Cr planned.
Risks
Primary risk remains the timeline for EU-GMP certification; Middle East geopolitical disruptions showed some initial impact.
Last quarter's promises, checked
Delivered
- Guided EU-GMP inspection in May 2026 → delivered May 4-7 2026 (= BEAT)
- Guided NIP/OTF revenue recovery in Q4 → delivered INR 254M (+sequential recovery) (= BEAT)
- Guided senior leadership expansion → delivered 3 VPs & 1 President hired (= BEAT)
Partly delivered
- Guided EU-GMP reinstatement process → delivered inspection complete, awaiting final report (= PARTIAL)
Missed
- Guided FY26 Revenue broadly in line with FY25 → delivered INR 3,744M (impacted by INR 200-250M MENA loss) (= MISS)
Investor Presentation filed with BSE, NSE: ZIMLAB. Summary written with AI assistance from the document.
Zim Laboratories Ltd: key numbers
- Share price
- ₹141.00
- Market cap
- ₹756.6 Cr
- Revenue (annual)
- ₹374.4 Cr
- Net profit (annual)
- ₹5.84 Cr
- P/E (TTM)
- 365.3×Sector 43.8×
- Promoter holding
- 30.30%-0.06% QoQ
- FII holding
- 0.17%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zim Laboratories Ltd
All →Zim Laboratories Investor Presentation: Key Takeaways
Q2 FY27 operating income ₹1,054 Mn (+18.9% YoY), EBITDA ₹77 Mn at 7.3% margin, PAT loss ₹21 Mn. EU-GMP cost base weighs on margins.
Zim Laboratories Q2 FY27 Results: Net Loss of ₹2 Cr, Loss Widens
Zim Laboratories Ltd reported revenue from operations of ₹105.4 Cr (+18.8% YoY) and a net loss of ₹2 Cr for Q2 FY27.
- Key figure
- Net loss ₹2 Cr
Zim Laboratories Board Meeting Date
Zim Laboratories has scheduled a board meeting on 4 November 2026 to consider its unaudited quarterly results for the quarter ended 30 September 2026. The trading window stays closed from 1 October to 6 November 2026.
Zim Laboratories Regulatory Approval
Zim Laboratories received TGA GMP certification from Australia's Therapeutic Goods Administration for its Nagpur manufacturing facility. The certification covers various dosage forms and is valid until June 2028.
- From
- Therapeutic Goods Administration (TGA), Australia
Zim Laboratories Credit Rating
CARE Ratings has reaffirmed the credit ratings of Zim Laboratories Limited for its bank facilities, revising the outlook on long-term facilities to negative.
Zim Laboratories Other Announcement
Zim Laboratories Limited filed a certificate confirming compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September 2026.